• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
In Vitro Fertilization Market in Asia Pacific - Country Analysis by End Users (Clinics, Hospitals, Surgical Centers, Clinical Research Institutes, Banks) Number of Cycles, Revenue, Market Share, Growth, Trends, and Forecast Through 2020 - Product Image

In Vitro Fertilization Market in Asia Pacific - Country Analysis by End Users (Clinics, Hospitals, Surgical Centers, Clinical Research Institutes, Banks) Number of Cycles, Revenue, Market Share, Growth, Trends, and Forecast Through 2020

  • Published: March 2014
  • Region: Asia
  • 155 Pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • Cadila Healthcare Ltd.
  • EMD Serono, Inc.
  • LG Life Sciences.
  • Sun Pharmaceutical
  • MORE

The IVF market in Asia Pacific is characterized by the growth in standards of living, growing number of couples delaying parenthood due to professional commitments and trends towards financial stability. The Asia Pacific IVF market, valued at $1.3 billion in 2012, is estimated to reach $4.2 billion by 2020. Delayed pregnancy in women is one of the major driving factors of the IVF market, as the chances of conceiving lowers with age. The success rate of getting pregnant with IVF technique is higher in the age group of 35-39. Other driving factors of the IVF market are rise in infertility rate due to rise in stress levels, change in life style and fertility related diseases.

Asia in particular is facing the challenge of aging population and lower work force replacement. These trends would impact the socio-economic development and progress. Many countries in Asia Pacific which are Japan, North and South Korea, China, Vietnam, Singapore and Thailand have fertility rates that are way below the replacement fertility levels. According to the East West center study, Japan, South Korea, Singapore and Taiwan Asia's prosperous economies have the lowest birth rate worldwide.

Taiwan READ MORE >

CHAPTER 1. REPORT OUTLINE
1.1. Report Description
1.2. Key Benefits
1.3. Coverage
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Models

CHAPTER 2. EXECUTIVE SUMMARY

CHAPTER 3. ASIA PACIFIC IN VITRO FERTILIZATION (IVF) MARKET (REVENUE AND NUMBER OF CYCLES)
3.1. Overview
3.2. IVF Pricing Trends by Contry
3.3. IVF Cycles by Country
3.4. Drivers
3.5. Restraints
3.6. Opportnities
3.7. Market by End User
3.7.1. Fertility clinics
3.7.2. Hospitals
3.7.3. Surgical centers
3.7.4. Banks
3.7.5. Clinical research institutes
3.8. Profiles of Major Players
3.8.1. Thermo Fisher Scientific Inc.
3.8.1.1. Company overview
3.8.1.2. Company snapshot
3.8.1.3. Financial overview
3.8.1.4. Market share
3.8.1.5. Strategic moves and developments
3.8.2. EMD Serono, Inc.
3.8.2.1. Company overview
3.8.2.2. Company snapshot
3.8.2.3. Financial overview
3.8.2.4. Market share
3.8.2.5. Strategic moves and developments
3.8.3. Sun Pharmaceutical
3.8.3.1. Company overview
3.8.3.2. Company snapshot
3.8.3.3. Financial overview
3.8.3.4. Market share
3.8.3.5. Strategic moves and developments
3.8.4. Cadila Healthcare Ltd.
3.8.4.1. Company overview
3.8.4.2. Company snapshot
3.8.4.3. Financial overview
3.8.4.4. Market share
3.8.4.5. Strategic moves and developments
3.8.5. LG Life Sciences.
3.8.5.1. Company overview
3.8.5.2. Company snapshot
3.8.5.3. Financial overview
3.8.5.4. Market share
3.8.5.5. Strategic moves and developments

CHAPTER 4. CHINA IVF MARKET (REVENUE AND NUMBER OF CYCLES)
4.1. Number of Cycles by Hospitals/Clinics
4.2. Market by End User
4.2.1. Fertility clinics
4.2.2. Hospitals
4.2.3. Surgical centers
4.2.4. Banks
4.2.5. Clinical research institutes
4.3. Drivers
4.4. Restraints
4.5. Regulatory issues, legislations and authorities
4.6. Insurance reimbursement scenario
4.7. Profiles of Major Players (Reproductive & and genetic Hospital Citic-Xiangya, Shenyang Hospital, China, IVF Center China, Shandong Provincial Hospital, China, Centre for Reproductive Medicine China)
4.7.1. Company overview
4.7.2. Company snapshot
4.7.3. Financial overview
4.7.4. Market share
4.7.5. Strategic moves and developments

CHAPTER 5. JAPAN IVF MARKET (REVENUE AND NUMBER OF CYCLES)
5.1. Number of Cycles by Hospitals/Clinics
5.2. Market by End User
5.2.1. Fertility clinics
5.2.2. Hospitals
5.2.3. Surgical centers
5.2.4. Banks
5.2.5. Clinical research institutes
5.3. Drivers
5.4. Restraints
5.5. Regulatory issues, legislations and authorities
5.6. Insurance reimbursement scenario
5.7. Profiles of Major Players (Hiroshima Hart Clinic, IVF Japan, The Advanced Reproductive Technological Institute (ARMT), Yoshida Ladies Clinic Reproductive ART Center, Iwaki-Women's Clinic)
5.7.1. Company overview
5.7.2. Company snapshot
5.7.3. Financial overview
5.7.4. Market share
5.7.5. Strategic moves and developments

CHAPTER 6. KOREA IVF MARKET (REVENUE AND NUMBER OF CYCLES)
6.1. Number of Cycles by Hospitals/Clinics
6.2. Market by End User
6.2.1. Fertility clinics
6.2.2. Hospitals
6.2.3. Surgical centers
6.2.4. Banks
6.2.5. Clinical research institutes
6.3. Regulatory issues, legislations and authorities
6.4. Insurance reimbursement scenario
6.5. Profiles of Major Players (Maria Fertility Hospital, Cha General Hospital, Seoul National University Hospital IVF Center, Dongtan Cheil Women's Clinic Ajou University)
6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Financial overview
6.5.4. Market share
6.5.5. Strategic moves and developments

CHAPTER 7. INDIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)
7.1. Number of Cycles by Hospitals/Clinics
7.2. Market by End User
7.2.1. Fertility clinics
7.2.2. Hospitals
7.2.3. Surgical centers
7.2.4. Banks
7.2.5. Clinical research institutes
7.3. Regulatory issues, legislations and authorities
7.4. Insurance reimbursement scenario
7.5. Profiles of Major Players (Bourn Hall Clinic, Southend Fertility and IVF Centre, Morpheus IVF Fertility Center, Bloom Fertility Center, Manipal Ankur, Cloudnine Fertility, Nova IVI Fertility)
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Financial overview
7.5.4. Market share
7.5.5. Strategic moves and developments

CHAPTER 8. AUSTRALIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)
8.1. Number of Cycles by Hospitals/Clinics
8.2. Market by End User
8.2.1. Fertility clinics
8.2.2. Hospitals
8.2.3. Surgical centers
8.2.4. Banks
8.2.5. Clinical research institutes
8.3. Regulatory issues, legislations and authorities
8.4. Insurance reimbursement scenario
8.5. Profiles of Major Players (Virtus Health, Monash IVF, Genea Limited, City Fertility, Flindersfertility)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Financial overview
8.5.4. Market share
8.5.5. Strategic moves and developments

CHAPTER 9. NEW ZEALAND IVF MARKET (REVENUE AND NUMBER OF CYCLES)
9.1. Number of Cycles by Hospitals/Clinics
9.2. Market by End User
9.2.1. Fertility clinics
9.2.2. Hospitals
9.2.3. Surgical centers
9.2.4. Banks
9.2.5. Clinical research institutes
9.3. Regulatory issues, legislations and authorities
9.4. Insurance reimbursement scenario
9.5. Profiles of Major Players (Fertility Associates New Zealand, Fertility Plus, Repromed)
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Financial overview
9.5.4. Market share
9.5.5. Strategic moves and developments

CHAPTER 10. SOUTH-EAST ASIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)
10.1. Number of Cycles by Hospitals/Clinics
10.2. Market by End User
10.2.1. Fertility clinics
10.2.2. Hospitals
10.2.3. Surgical centers
10.2.4. Banks
10.2.5. Clinical research institutes
10.3. Regulatory issues, legislations and authorities
10.4. Insurance reimbursement scenario
10.5. SINGAPORE IVF MARKET (REVENUE AND NUMBER OF CYCLES)
10.5.1. Number of Cycles by Hospitals/Clinics
10.5.2. Market by End User
10.5.2.1. Fertility clinics
10.5.2.2. Hospitals
10.5.2.3. Surgical centers
10.5.2.4. Banks
10.5.2.5. Clinical research institutes
10.5.3. Regulatory issues, legislations and authorities
10.5.4. Insurance reimbursement scenario
10.5.5. Profiles of Major Players (NUH IVF Centre, Thomson Fertility Centre, Mount Elizabeth Fertility Center, Parkview Fertility Centre, Raffles Fertility Centre)
10.5.5.1. Company overview
10.5.5.2. Company snapshot
10.5.5.3. Financial overview
10.5.5.4. Market share
10.5.5.5. Strategic moves and developments
10.6. MALAYSIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)
10.6.1. Number of Cycles by Hospitals/Clinics
10.6.2. Market by End User
10.6.2.1. Fertility clinics
10.6.2.2. Hospitals
10.6.2.3. Surgical centers
10.6.2.4. Banks
10.6.2.5. Clinical research institutes
10.6.3. Regulatory issues, legislations and authorities
10.6.4. Insurance reimbursement scenario
10.6.5. Profiles of Major Players (Subang Fertility Center Subang Jaya Hospital, TMC Fertility Center formerly known as Damansara Fertility center, Fertility Centre Scaudinavia, Concept Fertility Center (Malaysia), Medically Assisted Conception Centre)
10.6.5.1. Company overview
10.6.5.2. Company snapshot
10.6.5.3. Financial overview
10.6.5.4. Market share
10.6.5.5. Strategic moves and developments
10.7. INDONESIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)
10.7.1. Number of Cycles by Hospitals/Clinics
10.7.2. Market by End User
10.7.2.1. Fertility clinics
10.7.2.2. Hospitals
10.7.2.3. Surgical centers
10.7.2.4. Banks
10.7.2.5. Clinical research institutes
10.7.3. Regulatory issues, legislations and authorities
10.7.4. Insurance reimbursement scenario
10.7.5. Profiles of Major Players (Anugerah Fertility Center, Morula IVF, Fertility Centre, Siloam Hospitals Surabana, Aster Fertility Clinic, Yasmin IVF)
10.7.5.1. Company overview
10.7.5.2. Company snapshot
10.7.5.3. Financial overview
10.7.5.4. Market share
10.7.5.5. Strategic moves and developments
10.8. PHILIPPINES IVF MARKET (REVENUE AND NUMBER OF CYCLES)
10.8.1. Number of Cycles by Hospitals/Clinics
10.8.2. Market by End User
10.8.2.1. Fertility clinics
10.8.2.2. Hospitals
10.8.2.3. Surgical centers
10.8.2.4. Banks
10.8.2.5. Clinical research institutes
10.8.3. Regulatory issues, legislations and authorities
10.8.4. Insurance reimbursement scenario
10.8.5. Profiles of Major Players (Center for Reproductive Medicine, Victory Art Lab, CRM-MIA-Philippines)
10.8.5.1. Company overview
10.8.5.2. Company snapshot
10.8.5.3. Financial overview
10.8.5.4. Market share
10.8.5.5. Strategic moves and developments
10.9. THAILAND IVF MARKET (REVENUE AND NUMBER OF CYCLES)
10.9.1. Number of Cycles by Hospitals/Clinics
10.9.2. Market by End User
10.9.2.1. Fertility clinics
10.9.2.2. Hospitals
10.9.2.3. Surgical centers
10.9.2.4. Banks
10.9.2.5. Clinical research institutes
10.9.3. Regulatory issues, legislations and authorities
10.9.4. Insurance reimbursement scenario
10.9.5. Profiles of Major Players (Bangkok Fertility Center, Jetanin Institute for Assisted Reproduction, Perfect Woman Institute Piyavate Hospital, Ramathibodi Hosp, Mahidol University, Bangkok Thailand, Siriraj Hospital)
10.9.5.1. Company overview
10.9.5.2. Company snapshot
10.9.5.3. Financial overview
10.9.5.4. Market share
10.9.5.5. Strategic moves and developments
10.10. Vietnam IVF Market (revenue and number of cycles)
10.10.1. Number of Cycles by Hospitals/Clinics
10.10.2. Market by End User
10.10.2.1. Fertility clinics
10.10.2.2. Hospitals
10.10.2.3. Surgical centers
10.10.2.4. Banks
10.10.2.5. Clinical research institutes
10.10.3. Regulatory issues, legislations and authorities
10.10.4. Insurance reimbursement scenario
10.10.5. Profiles of Major Players (IVF Center of National Hospital of GB. Gyn, IVF Lab Tu Du Hospital Vietnam, IVF Van Hanh, IVFAS, Tu Du - Ho Chi Minh City Vietnam)
10.10.5.1. Company overview
10.10.5.2. Company snapshot
10.10.5.3. Financial overview
10.10.5.4. Market share
10.10.5.5. Strategic moves and developments

List of Tables

Table 1 Asia Pacific IVF Cycles By Country, 2012 – 2020 (Thousand)
Table 2 Asia Pacific IVF Revenue By Country, 2012 – 2020 ($Million)
Table 3 Asia Pacific IVF Cycles By End User, 2012 – 2020 (Thousand)
Table 4 Asia Pacific IVF Revenue By End User, 2012 – 2020 ($Million)
Table 5 Thermo Fisher Scientific Inc Business Overview
Table 6 Company Snapshot
Table 7 Emd Serono Inc Business Overview
Table 8 Company Snapshot
Table 9 Sun Pharmaceutical Business Overview
Table 10 Company Snapshot
Table 11 Cadila Health Care Business Overview
Table 12 Company Snapshot
Table 13 Lg Life Science Business Overview
Table 14 Company Snapshot
Table 15 China IVF Revenue By End Users, 2012 – 2020 ($Million)
Table 16 China IVF Cycles By End Users, 2012 – 2020 (Thousand)
Table 17 Cook Medical Inc Business Overview
Table 18 Company Snapshot
Table 19 Vetrolife Ab Inc Business Overview
Table 20 Company Snapshot
Table 21 India IVF Revenue By End Users, 2012 – 2020 ($Million)
Table 22 India IVF Cycles By End Users, 2012 – 2020 (Thousand)
Table 23 Sun Pharmaceutical Business Overview
Table 24 Company Snapshot
Table 25 Trivector Origio Scientific Business Overview
Table 26 Company Snapshot
Table 27 Lab IVF Asia Business Overview
Table 28 Company Snapshot
Table 29 Lg Life Science Business Overview
Table 30 Company Snapshot
Table 31 Cadila Health Care Business Overview
Table 32 Company Snapshot
Table 33 Korea IVF Revenue By End Users, 2012 – 2020 ($Million)
Table 34 Korea IVF Cycles By End Users, 2012 – 2020 (Thousand)
Table 35 New Zealand IVF Revenue By End Users, 2012 – 2020 ($Million)
Table 36 New Zealand IVF Cycles By End Users, 2012 – 2020 (Thousand)
Table 37 Australia IVF Revenue By End Users, 2012 – 2020 ($Million)
Table 38 Australia IVF Cycles By End Users, 2012 – 2020 (Thousand)
Table 39 Genea Biomedx Technologies Business Overview
Table 40 Company Snapshot
Table 41 Thermo Fisher Scientific Inc Business Overview
Table 42 Company Snapshot
Table 43 Japan IVF Revenue By End Users, 2012 – 2020 ($Million)
Table 44 Japan IVF Cycles By End Users, 2012 – 2020 (Thousand)
Table 45 Emd Serono Inc Business Overview
Table 46 Company Snapshot
Table 47 Birth Rate Of South-East Asia Per Thousand, 2012
Table 48 South-East Asia IVF Revenue By End Users, 2012 – 2013 ($Million)
Table 49 South-East Asia IVF Revenue By Country, 2012 – 2013 ($Million)
Table 50 South-East Asia IVF Cycles By Country, 2012 – 2013 (Thousand)
Table 51 South-East Asia IVF Cycles By End User, 2012 – 2013 (Thousand)
Table 52 Singapore IVF Revenue By End Users, 2012 – 2020 ($Million)
Table 53 Singapore IVF Cycles By End Users, 2012 – 2020 (Thousand)
Table 54 Pacific Healthcare Business Overview
Table 55 Company Snapshot
Table 56 Esco Technologies Business Overview
Table 57 Company Snapshot
Table 58 Emd Serono Inc Business Overview
Table 59 Company Snapshot
Table 60 Malaysia IVF Revenue By End Users, 2012 – 2020 ($Million)
Table 61 Malaysia IVF Cycles By End Users, 2012 – 2020 (Thousand)
Table 62 Indonesia IVF Revenue By End Users, 2012 – 2020 ($Million)
Table 63 Indonesia IVF Cycles By End Users, 2012 – 2020 (Thousand)
Table 64 Philippines IVF Revenue By End Users, 2012 – 2020 ($Million)
Table 65 Philippines IVF Cycles By End Users, 2012 – 2020 (Thousand)
Table 66 Thailand IVF Revenue By End Users, 2012 – 2020 ($Million)
Table 67 Thailand IVF Cycles By End Users, 2012 – 2020 (Thousand)
Table 68 Vietnam IVF Revenue By End Users, 2012 – 2020 ($Million)
Table 69 Vietnam IVF Cycles By End Users, 2012 – 2020 (Thousand)

List Of Figures

Fig. 1 Asia Pacific IVF Market By Country, 2013 & 2020 ($Million)
Fig. 2 Asia Pacific IVF Market By End Users, 2012 – 2020 ($Million)
Fig. 3 Percentage Of People Who Perceived Various Infertility Reasons (Singapore, Thailand, Indonesia And China)
Fig. 4 China Fertility Rate (Children Born/Women)
Fig. 5 Total Fertility Rate ( Children Born/ Women)
Fig. 6 Total Fertility Rate (Children Born/Women) - South Korea
Fig. 7 Total Fertility Rate ( Children Born/ Women)
Fig. 8 Total Fertility Rate ( Children Born/ Women)
Fig. 9 Total Fertility Rate ( Children Born/ Women)
Fig. 10 Singapore Fertility Rate Child Born/Women
Fig. 11 Malaysia Fertility Rate Child Born/Women
Fig. 12 Indonesia Fertility Rate Child Born/Women
Fig. 13 Philippines Fertility Rate Child Born/Women
Fig. 14 Thailand Fertility Rate Child Born/Women
Fig. 15 Vietnam Fertility Rate Child Born/Women

In-Vitro Fertilization (IVF) Market in Asia Pacific Will Reach $4.2 Billion by 2020

The IVF market in Asia Pacific stood at $1.3 billion in 2012 and is estimated to be $1.4 billion in 2013. The IVF market in the region is forecast to grow to $4.2 billion in 2020 at a CAGR of 17.1% during 2013 - 2020. The overall number of IVF cycles performed in the region stood at 329.3 thousand in 2013. The number of IVF cycles in Asia Pacific will continue growing with a fast pace during 2013 - 2020 to reach 779.4 thousand in 2020, registering a CAGR of 13.1% during the evaluation period.

In 2010, the Asia Pacific IVF market grown to become a $1 billion industry. The growth trajectory further consolidated with growing government interventions and support, especially in countries such Japan, Korea and Singapore where the lower fertility, aging population and lack work force has triggered severe implications.

Although the largest number of IVF cycles is performed in India, Australia is the largest contributor to overall region's revenue. Australia IVF market is estimated to be worth $369.7 million in 2013. The market is further expected to become a billion dollar industry in the country, garnering $1.1 billion in 2020 at a CAGR of 17.5% during 2013 - 2020. However, India IVF market is expected to be fastest growing country market with a CAGR of 17.9% during the same period. The faster revenue growth in India IVF market will be supported by the growth in cost per cycle due to increasing sophistications of procedures and advancement in technology.

Fertility clinics and specialty hospital plays crucial role in providing IVF treatment to couple seeking assistance for infertility treatment. With the success of specialized fertility centers such as Virtus Health Ltd (Australia) and Fortis Bloom Fertility and IVF Center (India), the IVF market in Asia Pacific has taken a leap forward. Specialized IVF clinics have been dominant in performing IVF cycles with about 161 thousand procedures performed in 2012. The segment is expected to have 371 thousand IVF cycles by the end of 2020 at a CAGR of 12.1% during 2013 - 2020, closely followed by Hospitals segment at 351 thousand in the same year. Surgical centers will exhibit fastest growth rate during the period; however, largely due to lower volume.

- Thermo Fisher Scientific Inc.
- EMD Serono, Inc.
- Sun Pharmaceutical
- Cadila Healthcare Ltd.
- LG Life Sciences.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos